CSLLY
Csl ADR

78
Mkt Cap
$46.98B
Volume
429,475.00
52W High
$44.86
52W Low
$22.83
PE Ratio
33.54
CSLLY Fundamentals
Price
$24.37
Prev Close
$24.20
Open
$23.55
50D MA
$27.07
Beta
0.71
Avg. Volume
605,998.45
EPS (Annual)
$1.55
P/B
2.50
Rev/Employee
$531,164.44
$87,722.37
Loading...
Loading...
News
all
press releases
CSLLY or ARGX: Which Is the Better Value Stock Right Now?
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
Zacks·13d ago
News Placeholder
More News
News Placeholder
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
Zacks·14d ago
News Placeholder
CSLLY or EXAS: Which Is the Better Value Stock Right Now?
CSLLY vs. EXAS: Which Stock Is the Better Value Option?
Zacks·1mo ago
News Placeholder
CSLLY vs. EXAS: Which Stock Is the Better Value Option?
CSLLY vs. EXAS: Which Stock Is the Better Value Option?
Zacks·2mo ago
News Placeholder
CSL Limited (CSLLY) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for CSL Limited (CSLLY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·2mo ago
News Placeholder
CSLLY or TECH: Which Is the Better Value Stock Right Now?
CSLLY vs. TECH: Which Stock Is the Better Value Option?
Zacks·2mo ago
News Placeholder
Australia’s CSL hits 6-wk high on report of R&D division job cuts
Investing.com-- Shares of Australia’s CSL Ltd (ASX:CSL) climbed over 3% on Tuesday after the Australian Financial Review reported the biotech giant is planning to cut around one-third of its roughly 2,500-strong global R&D workforce.
investing.com·9mo ago
News Placeholder
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
ALKS vs. CSLLY: Which Stock Is the Better Value Option?
Zacks·9mo ago
News Placeholder
KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?
Zacks·10mo ago
News Placeholder
CSL lifts HY profit as plasma sales jump, offsets flu vaccine weakness
Investing.com-- Australian biopharmaceutical giant CSL Ltd (ASX:CSL) reported a rise in half-year net profit, driven primarily by robust performance in its blood plasma division.
investing.com·1y ago
<
1
2
...
>

Latest CSLLY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.